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Individual Prediction in Prostate Cancer
Studies Using a Joint
Longitudinal-Survival-Cure Model
Menggang Yu, Jeremy Taylor, and Howard M. Sandler

Abstract

For monitoring patients treated for prostate cancer, Prostate Specific Antigen (PSA)
is measured periodically after they receive treatment. Increases in PSA are suggestive of recurrence of the cancer and are used in making decisions about possible new treatments. The data from studies of such patients typically consist of
longitudinal PSA measurements, censored event times and baseline covariates.
Methods for the combined analysis of both longitudinal and survival data have
been developed in recent years, with the main emphasis being on modeling and
estimation. We analyze data from a prostate cancer study that has been extended
by adding a mixture structure to the survival model component of the model. Here
we focus on utilizing the model to make individualized prediction of disease progression for censored and alive patients.
In this model each patient is assumed to be either cured by the treatment or susceptible to clinical recurrence. The cured fraction is modeled as a logistic function of
baseline covariates, measured before the end of the radiation therapy period. The
longitudinal PSA data is modeled as a non-linear hierarchical mixed model, with
different models for the cured and susceptible groups. To accommodate the heavy
tail manifested by the data and possible outliers, we use a t-distribution for the
measurement error. The clinical recurrences are modeled using a time-dependent
proportional hazards model for those in the susceptible group where the time dependent covariates include both the current value and the slope of post-treatment
PSA profile. Estimates of the parameters in the model are obtained by the Markov
chain Monte Carlo (MCMC) technique. Residuals from the longitudinal model
are plotted for model checking. The model is used to give individual predictors

for both future PSA values and the predicted probability of recurrence up to four
years in the future. These predictors are compared with observed data from a validation data set consisting of further follow-up of the subjects in the study. There
is good correspondence between the predictions and the validation data.
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Abstract
For monitoring patients treated for prostate cancer, Prostate Specific Antigen (PSA) is
measured periodically after they receive treatment. Increases in PSA are suggestive of recurrence of the cancer and are used in making decisions about possible new treatments. The data
from studies of such patients typically consist of longitudinal PSA measurements, censored
event times and baseline covariates. Methods for the combined analysis of both longitudinal
and survival data have been developed in recent years, with the main emphasis being on modeling and estimation. We analyze data from a prostate cancer study in which the patients are
treated with radiation therapy using a joint model that has been extended by adding a mixture
structure to the survival model component of the model. Here we focus on utilizing the model
to make individualized prediction of disease progression for censored and alive patients.
In this model each patient is assumed to be either cured by the treatment or susceptible to
clinical recurrence. The cured fraction is modeled as a logistic function of baseline covariates,
measured before the end of the radiation therapy period. The longitudinal PSA data is modeled
as a non-linear hierarchical mixed model, with different models for the cured and susceptible
groups. To accommodate the heavy tail manifested by the data and possible outliers, we
use a t-distribution for the measurement error. The clinical recurrences are modeled using
a time-dependent proportional hazards model for those in the susceptible group where the
time dependent covariates include both the current value and the slope of post-treatment
PSA profile. Estimates of the parameters in the model are obtained by the Markov chain
Monte Carlo (MCMC) technique. Residuals from the longitudinal model are plotted for model
checking. The model is used to give individual predictions of both future PSA values and the
predicted probability of recurrence up to four years in the future. These predictions are
compared with observed data from a validation data set consisting of further follow-up of the
subjects in the study. There is good correspondence between the predictions and the validation
data.
KEY WORDS: Prostate cancer data; Joint models; Markov chain Monte Carlo; Longitudinal models; Survival models; Cure models.
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Introduction

There are many circumstances in which both a repeatedly-measured biomarker outcome and the
elapsed time to an event are collected on each individual in a medical study. These biomarkers
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are frequently important health indicators that represent the progression of a disease. Such data
will typically have additional features and complications associated with it, including the presence
of treatment group indicators and baseline covariates, measurement error in the biomarkers and
right censoring of the event time with the possibility of dependent censoring. Joint models for
both the marker process and the survival data have been developed in recent years to analyze
such data. Estimation of the parameters can be done through a two-stage approach (e.g. Tsiatis
et al. 1995, Bycott and Taylor 1998) and a likelihood based approach (e.g. Faucett and Thomas
1996, Wulfsohn and Tsiatis 1997, Henderson et al. 2000, Wang and Taylor 2001, Xu and Zeger
2001, Pauler and Finkelstein 2002, Law et al. 2002). A review on these two approaches can be
found in Yu et al. (2004).
PSA is a well known biomarker for prostate cancer used both for screening and for monitoring
response to treatment. It is a routine laboratory assay obtained in a blood sample and thus is
easy to acquire. Common treatments for patients with local prostate cancer include radiation
therapy and surgery. After treatment, clinical recurrence of disease may occur after a period of
time. Clinicians and patients monitor the outcome of the treatment by measuring PSA regularly
and slight changes or increased values can be a source of great concern and anxiety. In patients
who undergo radiation therapy, a sharp rise in PSA after the initial decline is an indicator of
treatment failure, and clinical recurrence (reappearance of tumor, either local recurrence or distant metastasis) is expected to follow, although it could be many years before there is clinical
manifestation of the recurrence. If the PSA remains low and stable this is an indication that the
tumor is not regrowing in the patient. Thus the longitudinal PSA could be useful for predicting
cancer recurrence for patients after radiation therapy. The latest value of PSA and the slope of
its increase can be very informative about the progression of disease and the hazard of a clinical
recurrence. If the pattern of PSA is suggestive of an increased risk of clinical recurrence, the patients may be put on new therapy based solely on this pattern of PSA, typically hormonal therapy
with substantial potential side effects, to slow down progression of the disease. Thus methods
that enhance early detection of recurrence and accurate prediction of future disease progression
for an individual patient based on the pattern of PSA values can have great utility.
A feature in many cancer applications is the fact that some of the patients may have their
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tumor completely killed by the treatment, and so will never experience clinical recurrence. These
patients are considered to be ”cured”. We incorporate this aspect of the study into our joint
modeling by using mixture cure models (e.g. Farewell 1982, Kuk and Chen 1992, Taylor 1995).
The longitudinal-survival-cure model we adopt here has been used in Law et al. (2002) and Yu
et al. (2004). The previously developed model is extended in a number of ways. Besides including
additional baseline covariates, we use a time-dependent proportional hazards model depending on
hormonal therapy (HT), the current slope, as well as the current value of PSA. To accommodate
heavy tails manifested in the longitudinal data and possible outlier, t distributions are used for the
measurement error. This model allows estimation of a number of different aspects, including both
how PSA changes over time and how this is influenced by other covariates and how PSA influences
the hazard of clinical recurrence. However the main focus of the article is on utilizing the model
to make individualized predictions for disease progression. Specifically, we predict future PSA
values and cancer recurrence probabilities for censored and alive patients. The performance of
the prediction is evaluated using a validation data set obtained through further follow-up for these
patients.
The task of using a series of biomarker values is considerably more complicated than using
a single value, for early detection of disease or monitoring disease progression. The hope is that
by using all the data from the serial observations this will lead to an earlier and more precise
prediction of future disease progression. There are a few examples of using serial observations in
the statistical literature, all involving fairly complicated models and considerable computation.
These include using CA125 for early detection of ovarian cancer (Skates et al. 2001), using PSA
for early detection of prostate cancer (Slate and Cronin 1997), and using PSA for detecting disease
recurrence in prostate cancer (Pauler and Finkelstein 2002).
The rest of this article is organized as follows. In Section 2, we describe two data sets, an
analysis data set and a validation data set. In Section 3, we describe a joint cure model. Section
4 presents the Bayesian estimation schemes for the model. Section 5 lists the results. Section
6 uses the model to make individualized predictions and Section 7 assesses the performance of
the prediction by comparison to a validation dataset. Finally, we conclude the article with a
discussion section.
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2

Data

The joint model is developed and fit to one dataset, called the analysis dataset. Predictions
derived from this dataset are compared with observations in a second dataset, called the validation
dataset, which consists of further follow-up on the subjects in the analysis dataset.

2.1

Analysis dataset.

The data consist of 928 patients with localized prostate cancer, who were treated with external
beam radiation therapy at the University of Michigan between July 1987 and February 2000.
Patients were excluded from this analysis if they received planned hormonal therapy before the end
of the radiation therapy regimen. The baseline variables were age, radiation dose, and duration,
T-stage(a measure of the size and location of the tumor), Gleason score ( a measure of the
aggressiveness of the tumor) and pre-treatment PSA. Earlier version of these data are described
elsewhere (Sandler et al. 2000). Post treatment PSA was measured at approximately 6 month
intervals. The median number of PSA values per patient was 6 (range 1-29). The total number
of PSA measures is 6150. The maximum time between treatment and a PSA measurement is
145 months. During the follow-up period, up to February 2001, 146 patients experienced clinical
recurrences, 70 had local recurrence, 72 had distant metastases and 4 had regional failure as their
first clinical recurrence. Of the 782 censored patients, 143 died of other causes before any clinical
recurrence and 639 were censored at February 2001 or were lost to follow-up prior to that date.
Fifty six patients received hormonal therapy prior to any clinical recurrence, of these 15 had a
later clinical recurrence.
For patients who were given hormonal therapy, only PSA measured prior to the hormonal
therapy are used. For patients who developed clinical recurrence, the PSA measurements before the endpoint are included and for the other (censored) patients, all PSA measurements are
included.
Figure 1 are plots of post-treatment PSA measurements for 20 randomly selected patients
from each of three categories of patients; those who experienced a clinical recurrence, those who
were censored and did not receive HT, and those who received HT prior to a recurrence. We
can see a clear pattern of decline in PSA after therapy, followed potentially at a later time by an
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Figure 1: Observed post-treatment PSA measurements
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increase. The PSA profiles are different among the three groups. We see a clear trend of PSA
increase at the later follow-up time after the initial decline for failed patients while we see much
flatter curves for censored patients. For patients who received HT as a salvage therapy, we also
see a rising trend of the PSA measurements. This is expected because HT is usually given because
of a rising pattern of PSA.

2.2

Validation dataset.

The validation dataset consists of all data collected on these 928 patients after February 2001
and available in September 2003. We restrict attention to the 612 patients who were alive at
the last contact time in the analysis dataset, and were not known to have experienced a clinical
recurrence or received hormonal therapy prior to February 2001. There were 541 patients where
new follow-up information was available. Amongst these 541 patients, 472 were alive at the end of
the this new follow-up, 63 died from other causes not related to prostate cancer and 6 died from
prostate cancer. The median additional follow-up time is 30 months. There were 329 patients
with additional PSA values, these patients provided 992 PSA measurements within three years of
the previous last follow-up date. Fifteen of the patients developed clinical recurrence in the new
follow-up period, 6 of these 15 had HT before the recurrence, an additional 14 have received HT
without any clinical recurrence.

3

Notation and Model Specification

Let zi = {zi1 , · · · , ziq } be the q fixed baseline covariates for subject i. The ni post-treatment PSA
measurements of an individual are denoted by vector ỹi = (ỹi1 , · · · , ỹini ), with the corresponding
measurement time vector t̃i = (ti1 , · · · , tini ). We denote log transformed post-treatment PSA
measurements by yi = (yi1 , · · · , yini ) ≡ (log(ỹi1 + 1), · · · , log(ỹini + 1)). This transformation is
used so that residuals better satisfy the assumptions of symmetry and homogeneity of variance.
Let ti be the observed follow-up time, and δi be the corresponding censoring indicator. The
cure group indicator is denoted by Di . For a subject i in the susceptible group, Di is equal to 1;
otherwise, it is equal to 2.
Let xi,obs = {yi , ti , δi } be the observed response data for subject i and Xobs = {xi,obs , i =
1, · · · , n}. Denote Z = {zi , i = 1, · · · , n}.
6
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Incidence model
The probability of an individual i to be in the susceptible group is given by the logistic function:
P (Di = 1 | b, zi ) =

exp(b0 + b1 zi1 + · · · + bq ziq )
1 + exp(b0 + b1 zi1 + · · · + bq ziq )

(1)

Longitudinal model
The post-treatment PSA data are modeled by a hierarchical nonlinear mixed effects model.
The response model of PSA is given by
Yij ≡ log(Yeij + 1) = log(P SA∗ij + 1) + ǫij , j = 1, · · · , mi

(2)

where P SA∗ij ≡ P SA∗ (tij ) is the ”true” PSA process at time tij the expression of which is
defined below, ǫij is the measurement error at time tij . We assume that the measurement error
terms ǫij follow a mean 0 t-distribution with degree of freedom ν > 0, and variance σe2 for all
j = 1, · · · , ni ; i = 1, · · · , n. We note that the t-distribution can be written as a scale mixture of
normal distributions (Lange et al. 1989), that is, we can introduce a latent variable ζij such that

ǫij | ζij ∼ N (0, σe2 /ζij ) with ζij ∼ Gamma ν/2, ν/2

The ”true” PSA marker process is modeled by a nonlinear exponential decay and exponential
growth model (Zagars and Pollack 1993):
P SA∗i (t) = ri1 e−ri2 t + ri3 eri4 t

(3)

ri1 , ri2 , ri3 and ri4 are the unobserved random effects for subject i (ri1 , ri2 , ri3 and ri4 > 0). The
term (ri1 + ri3 ) is the intercept of the post-treatment PSA profile, ri2 is the rate of decline of PSA
following treatment, while ri4 is the rate of rise following the initial decline.
Depending on the patient’s cure status Di , we use different mixed effect model parameters for
the true underlying marker profile. For the random effects of a subject i in the susceptible group,
we assume



(1)
Ri | Di = 1, zi ∼ N (Zi µ1 , Σ1 )

(4)
(1)

where Ri denotes the log random effects (log ri1 , log ri2 , log ri3 , log ri4 ) and Zi µ1 is the mean
(1)

vectors of the random effects in the susceptible group, Zi

= (I4 ⊗ z∗i )T is a Kronecker product

between I4 and z∗i , a vector of baseline covariates.
7
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For the random effects of a subject i in the cured group, we assume that the rate of rise
denoted by ri4 is close to zero:
( 



(2)
Ri(−4) | Di = 2, zi ∼ N Zi µ2 , Σ2



Ri4 | Di = 2 ∼ N −6, σ44

(5)

(2)

where Ri(−4) ≡ (log ri1 , log ri2 , log ri3 ), Ri4 ≡ log ri4 , Zi µ2 is the mean vector of these random
(2)

effects in the cure group where Zi

= (I3 ⊗ z∗i )T . The mean −6 for Ri4 for a cured patient is

chosen from the fact that PSA level doubles on average in about 20 years for a healthy male.
Hence the covariance matrix Σ∗2 of Ri for the cured group is block-diagonal with two blocks, Σ2
and σ44 . We assume a normal model for Ri4 to allow for variations of the growth in the cured
group.
Conditional failure time model
Conditional on the unobserved random effects, the relative hazard function of the event time
t is given by



λ t | Di = 1, Ri , zi = λ0 (t|η) exp γ P SAi (t) + ω g sli (t)) + κHTi (t) + β ′ zi

(6)

where the baseline hazard function is taken to be Weibull λ0 (t|η) = αλtα−1 , g(·) is some continuous function, sli (t) = ∂P SAi (t)/∂t is the slope of P SAi (t) ≡ log(P SA∗i (t) + 1) at time t,
and HTi (t) is a function of t representing HT effect. Our choice of including the slope of the
underlying PSA curve is based on commonly used empirical criteria in characterizing prostate
cancer progression such as PSA doubling time and PSA velocity. Due to the fact that only a
small number of patients receiving HT and an even smaller number of these patients had events,
we take a simple function form for HT, HTi (t) = 1 −

t−thi
a I(thi

< t < thi + a) where thi is the

time of the HT if the patient has HT, a is a constant to be determined, and I(·) is the indicator
function. Hence HTi (t) = 1 when t = thi and it decreases linearly to 0 at t = thi + a. The
reason for taking a decreasing function for HT is that the effect of HT tends to diminish as time
progresses.
We explore the appropriate functional form g for sli (t), a in HTi (t), and the degree of freedom
ν in the t-distribution through exploratory analysis. As an initial step, we fit a joint-longitudinalsurvival cure model to the analysis data set without taking any transformation of slope, that is,
8
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g(x) = x, in the conditional failure time model and normal measurement error for the longitudinal
data. Then we use results of this modeling fitting to determine g, a, and ν. To choose a value
for a, we regard all patients with clinical events or HT, and patients with estimated probability
of D = 1 greater than 0.6 as ”susceptible” and then we fit a Cox model to this group. Then
we vary a from 0 to 120 and then compare the partial log-likelihood of each model fitting, and
find that 60 may be a good choice for a. To determine a transformation g(·), we use the Poisson
and spline-based method described in Therneau and Grambsch (2000) (pg. 120) to explore the
functional form for g(·). We find that a square root transformation maybe appropriate. The
residuals from the fitting of the longitudinal model is used to determine ν. The degree of freedom
5 is suggested for ν from plots of residuals quantiles versus quantiles of standard normal and
t-distributions with various degrees of freedom.

4

Estimation Using Markov Chain Monte Carlo

4.1

Prior Distributions

We fit the model using a MCMC technique. Data driven vague normal priors are taken for
b, γ, ω, κ, β. Specifically, we treat all censored patients with censoring time > 60 months and last
longitudinal PSA < 4 as cured. Then we fit a logistic model to all patients in order to get the
mean of the normal prior for b, we set the prior variance of each component of b as 16, which
is approximately 100 times the variance estimate from this simple method. Similarly, we obtain
prior means of γ, ω, κ, β by fitting a Cox proportional hazard model to non-cured patients from
the above simplified rule and using the nearest preceding value of PSA as the current value. The
prior variances are obtained by inflating approximately 100 times the variance estimate from the
simpler method.
Vague conjugate priors are used for other parameters. Independent multivariate normal distributions are used as prior distributions for each row of µ1 and µ2 . The prior of σe2 has an inverse
Gamma distribution with mean 1 and variance 10. The prior for Σ1 is from inverse Wishart
distribution Inv − W ishartν10 (S01 ) with mean S01 /(ν10 − 5). We take the mean as the estimated
Σ̂1 from simplified analysis using the longitudinal data alone and the degree of freedom ν10 = 20,
which is close to the dimension of Σ1 . From the posterior distribution of Σ1 , the prior specifi9
Hosted by The Berkeley Electronic Press

cation has small impact on the posterior distribution. Similarly the prior for Σ2 is from inverse
Wishart distribution Inv −W ishartν20 (S02 ) with the degree of freedom ν20 = 19, which is close to
the dimension of Σ2 .
An inverse Gamma distribution with mean 0.1 and variance 2 is used as the prior for σ44 . The
reason we use 0.1 for the mean is that there should be less variation for ri4 for the cured group.
From the posterior distribution of σ44 , we can see that the posterior is dominantly determined by
data. For the parameter λ of the baseline hazard, the prior is taken from a gamma distribution
with mean 0.01 and variance 100. For the shape parameter α of λ0 (t), we assume that it has
uniform prior on [0.5, 2.5].

4.2

Posterior Distributions and Implementation Details

The posterior distributions for all the parameters can be obtained from the product of full complete
data likelihood and prior distributions. The full complete data likelihood is determined by model
components (1), (2), (3), (4), (5), and (6) specified in section 3 given the fully observed data
xobs = {zi , yi , ti , δi , i = 1, · · · , n}.
"
Y nY
I(Di =2) o Y
I(Di =1)
ζij
N yij | Di = 2, Ri , σe2 /ζij
N yij | Di = 1, Ri , σe2 /ζij
L =
j

i

·f t | Ri , zi , β, γ, ω, κ, η
·

I(δi =1)

S t | Ri , zi , β, γ, ω, κ, η

I(Di =1)I(δi =0)

o
Yn
h(Ri | Di = 1, µ1 , zi )I(Di =1) h(Ri | Di = 2, µ2 , zi )I(Di =2)

#

j

i

o
Yn
·
P (Di = 1 | b, zi )I(Di =1) P (Di = 2 | b, zi )I(Di =2)

(7)

i



where N yij | Di = 1, Ri , σe2 /ζij and N yij | Di = 2, Ri , σe2 /ζij are the normal density for trans-

formed longitudinal data from (2) conditioning on their incidence group, f (t | ·) = λ(t | ·)S(t | ·) is

the density function of the conditional failure time model for subjects in the susceptible group.
h(Ri | Di = 1, µ1 , zi ) and h(Ri | Di = 2, µ2 , zi ) are densities for random effects conditioning on
their incidence group from (4) and (5). The expressions for all conditional posterior distributions
can be found in Yu (2004).
Adaptive Rejection Sampling (Gilks and Wild 1992) is used for b, γ, β, ω, κ since the posteriors
are log-concave. A random walk chain (Metropolis et al. 1953 and Casella and George 1992)
10
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algorithm is used for random effects Ri . Mean 0 Normal distributions are used for perturbation
to get candidate draws. The standard deviations are chosen so that the acceptance rate is about
0.20. Similarly a random walk chain is used for α. The continuous covariates are centered to
improve convergence and reduce correlation between them. For censored subjects we drew two
sets of values of Ri , one under the assumption that Di = 1 and one under the assumption Di = 2.
This facilitated drawing a new value of Di in the chain.
The program is written in c++. It takes an average of 56 hours to run 15,000 iterations
on a Sun workstation. We use both multiple sequences (Gelman and Rubin 1992) method and
traceplots for population parameters to check for convergence of the Gibbs sampler in the early
exploratory stage of checking convergence. The final results are based on 10,000 draws after 5,000
iterations of burn-in.

5

Results

The main parameter estimates from the model fitting are listed in Table 1. We show the posterior
mean and standard deviation derived from the posterior draws of the parameters in the table. We
compare the ratio of posterior mean over posterior standard deviation of a parameter and then
compare with 1.96 to assess the significance of covariate effects.
Table 1 shows the result for the incidence model (1), we find that a patient’s tumor stage,
baseline PSA and total dose of radiation are significantly related to the probability of cure in the
expected direction. Gleason score, age, and Duration of the treatment are not significant.
For the conditional failure time model, we see that the slope of PSA profile affects the hazard
of cancer recurrence greatly. Large slope highly increases the hazard. HT reduces the risk while
higher Gleason score and baseline PSA are associated with elevated risk for not cured patients.
We use residuals from the fitting of the longitudinal model, yij − P[
SAij , to check the model
where
K
i
o
n (k) o
h (k)
n
(k)
(k)
1 X
[
log eRi1 exp −eRi2 tij + eRi3 exp eRi4 tij + 1 .
P SAij =
K

(8)

k=1

(k)

(k)

(k)

(k)

with Ri1 , Ri2 , Ri3 , and Ri4 are from the MCMC output for k = 1, · · · , K.
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Table 1: Parameter Estimates in the Joint Models

The incidence model
Intercept
I(T stage = 1)
I(T stage = 2)
ln(bPSA+1)
Gleason
Age at RT
Total Dose
Duration

Est
1.857
-1.512
-1.518
0.769
0.106
-0.011
-0.086
-0.029

S.D.
0.605
0.535
0.527
0.204
0.094
0.018
0.039
0.022

Est/S.D.
3.070
-2.826
-2.881
3.771
1.129
-0.641
-2.209
-1.322

The failure time model
I(T stage = 1)
I(T stage = 2)
ln(bPSA+1)
Gleason
Total Dose
P SA(t)
Sqrt Slope
HT

-1.133
-0.337
0.230
0.227
0.034
0.211
5.326
-2.865

0.357
0.237
0.119
0.077
0.031
0.086
0.769
0.678

-3.172
-1.423
1.941
2.945
1.096
2.451
6.928
-4.228

Baseline hazard
α
λ

1.093
0.002

0.123
0.001

8.869
1.727

Measurement error
σe2

0.013

0.005

27.3

We plotted the absolute residuals |yij − P[
SAij | versus predicted log-transformed current PSA
from (8), baseline PSA, Gleason score and Tumor stages, we see no clear trend in any of these
plots. Figure 2 shows a normal and a t5 quantile-quantile plots of the residual. We see that the t
distribution with 5 degrees of freedom is reasonable. We note that using a t distribution has the
ability to accomodate outliers but had little impact on the results of parameter estimates listed
in Table 1.
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Figure 2: Residual plots for longitudinal model
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Model Predictions


Suppose we wish to forecast the t0 months recurrence free probability P Ti > ti +t0 | Xobs , Z

for

a censored patient i (still alive at the censored time ti ) based on the available data Xobs , Z. Let Ω ≡
{b, σe , µ1 , µ2 , Σ1 , Σ2 , γ, ω, κ, α, λ} denote the population parameters in the joint models described
(k)

(k)

in Section 3. With K draws {Ω(k) , Di , Ri
k = 1, · · · , K} from the posterior distribution



Ω, Di , Ri | Xobs , Z , we can approximate P Ti > ti + t0 | Xobs , Z by
K
1 X 
(k)
(k)
P Ti > ti + t0 | Ω(k) , Di , Ri , Xobs , Z
K
k=1

K
i

1 Xh
(k)
(k)
(k)
(k)
I(Di = 2) + I(Di = 1)P Ti > ti + t0 | Ω(k) , Di = 1, Ri , Xobs , Z
=
K

(9)

k=1

i

(k)
(k)
where P Ti > ti + t0 | Ω(k) , Di = 1, Ri , Xobs , Z
is calculated from (6).

We consider two conditional survival curves 4 years after the last contact time for patient


i, P Ti > ti + t | Xobs , Z, no HT in [ti , ti + t] and P Ti > ti + t | Xobs , Z, HT at time ti for
13
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Figure 3: Individual prediction of distribution of time to clinical recurrence (up to 4 years) for
4 selected censored patients. The left-side vertical axis is shown on a log(PSA+1) transformed
scale. The vertical line indicates the time of last contact. The right-side vertical axis shows the
probability of being recurrence free from the date of last contact.
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Figure 4: Uncertainty involved with the prediction of distribution of time to clinical recurrence (up
to 4 years) for 4 selected censored patients. The left-side vertical axis is shown on a log(PSA+1)
transformed scale. The vertical line indicates the time of last contact. The right-side vertical axis
shows the probability of being recurrence free from the date of last contact.
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t ∈ (0, 48]. By putting these two prediction curves together, we can see the effect of HT on
the patient’s survival and help aid the decision of whether to give HT for him. Uncertainty

of the prediction probability, say, P Ti > ti + t | Xobs , Z, no HT in [ti , ti + t] can be shown

(k)
(k)
(k)
(k)
by evaluating P Ti > ti + t | Ω(k) , Di , Ri , xobs , zi for different draws {Ω(k) , Di , Ri } and
calculating the variability of the predicted probability.

Figure 3 shows the pattern of PSA and the predicted probability of future clinical recurrence
from the date of last contact, with and without the addition of hormonal therapy at the last
contact time, for four selected patients. Figure 4 shows the uncertainty of the prediction of
clinical recurrence without HT, for the same set of four patients. The estimated probability of
eventual recurrence for each patient is also listed in this figure.
Patient (a) and (b) have long follow up time, (c) has medium follow-up time and (d) has
relatively short follow up time. The patients were selected to illustrate a range of PSA patterns
and predictions. The magnitude of the potential impact of hormonal therapy (HT) can be seen.
For patient (a), there is a clear pattern of increasing PSA, suggesting eventual clinical recurrence.
Patient (a) has a steep rise which leads to a high probability of recurrence within 4 years. For
patient (b) the favorable pattern of PSA post-treatment suggests cure, which corresponds to
the almost horizontal predicted clinical recurrence curve. There is little probability of eventual
recurrence (0.001) for this patient. Although the PSA values for patient (c) are relatively low, he
has a clearly rising pattern, this leads to a quite high probability of eventual recurrence (0.676).
Patient (d) has very short follow-up leading to considerable range of predicted probabilities of
recurrence within 4 years.
The prediction of future PSA values for patients who are censored, alive and did not receive
(k)

HT can be calculated from the draws in the Markov chain. For a posterior draw Ri , the
(k)

(k)

(k)

(k)

(k)

predicted (log-transformed) PSA at time t is P SAi (t) = log(ri1 e−ri2 t +ri3 eri4 t +1). By adding
(k)

corresponding measurement error ǫi

∼ t5 {0, (σe2 )(k) }, a 95% point-wise predictive interval for
(k)

(k)

log-transformed PSA is then formed using 2.5% quantile to 97.5% quantile of {P SAi (t)+ǫi , k =
1, 2, · · · , m} for m draws. Examples of these predictive intervals on the original PSA scale are
shown as shaded regions for the four patients in Figure 5.
Note that the construction of predictive intervals at each time point is based on the assumption
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that HT is not given and that clinical recurrence events and death could be eliminated. This is
not the same as the assumption that the patient is alive and is not given HT.
We note that patients (a) and (b), who have lots of data, have fairly narrow prediction intervals,
whereas patient (c) and (d) have less follow-up and thus wider prediction intervals. We envision
a graph like this would also be useful in monitoring the progression of the patient, for example if
a new PSA value is measured and it falls outside the shaded region then this is indicative of the
patient doing either worse than or better than expected. After a new measurement is obtained
new graphs could be produced, thus giving real-time monitoring of a patient’s progression.

7
7.1

Validation
Validation of the Longitudinal Model

The + symbols in the graphs in Figure 5 are PSA measurements obtained from the validation
dataset for these 4 patients, all the values fall within the 95% prediction intervals. Patient (c)
had a distant metastasis at 61 months after radiation therapy. Patient (a), (b), and (d) have
had no clinical recurrence in the validation dataset in the follow-up period. Table 2 shows the
proportion of future PSA values amongst all available future data which were within the 95%
prediction intervals, we see very good correspondence with the expected 95% level for all years.
Table 2: Prediction and Validation of the Longitudinal Model
Yearly intervals
0-1 Year
1-2 Year
2-3 Year

7.2

Total # PSA
281
407
304

Above 97.5%
1.8%
3.4%
3.3%

Between 2.5% and 97.5%
95.5%
92.8%
91.2%

Below 2.5%
1.1%
2.9%
2.3%

Validation of Conditional Failure Time Model

Table 3 compares the expected events and observed events. For a censored and alive subject i
with survival information (ti , δi = 0) with follow-up information (t∗i , δi∗ ), the expected number of

events within (ti , t∗i ] is P Ti < t∗i | Xobs , Z . Now to calculate the expected number for 1 year, we

get the follow-up time for all censored (δi = 0) subjects, t∗i − ti . If t∗i − ti > 12, we set t0 = 12, else
17
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Figure 5: Prediction and validation of the longitudinal model
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Table 3: Comparison of the Expected Events and Observed Events

Expected # events
Observed # recurrence
Observed # recurrence or HT

0-1 Year
11
6
10

0-2 Years
20
10
20

0-3 Years
26
11
24


we use t0 = t∗i − ti in P Ti > ti + t0 | Ti > ti . By summing over i, we get the expected number

of events in 0 ∼ 1 year. Similarly we can calculate expected number of events for 0 ∼ 2 years and

0 ∼ 3 years. From Table 3, we can see that the observed number of recurrence events is much
less than the expected number of events for all periods. One reason is that some patients get HT
because of elevated PSA. But if we count HT as failure, then the numbers are much closer.
Another way to validate the survival model is to calculate the probability of recurrence within

3 years after the last contact time in the analysis data, P Ti ≤ ti + 36 | Xobs , Z, no HT in [ti , ti +

36] , for any censored and alive patient who had no HT before ti , and then compare with observed
recurrence or HT. The calculated Kaplan-Meier estimate of the three year recurrence or hormonal
therapy probability is shown in Figure 6 for five groups categorized by the estimated probability
of recurrence within 3 years. The results show that a larger proportion of recurrences or HT

patients in the groups with the higher predicted probability, this provides support for the validity
of the model. For those who have small predicted probability (< 0.01), there were no recurrence
(1 received HT) within 3 years from the last contact time in the analysis data.

7.3

Sensitivity to Priors and Model Assumptions

Due to the large number of patients and longitudinal observations we have in the study, the posterior distributions of population parameters are dominated by data. So we expect our results to be
quite robust to most prior specifications. Our limited experience with various prior specifications
confirm that this is indeed the case for most parameters. We suspect that the variance term
σ44 for the distribution of Ri4 in the cured group, together with the prior mean −6, might have
some effects on the classification of the cure status of patients and hence affect the estimates of
population parameters. We set a fairly informative prior for σ44 to restrict the variation of Ri4 for
the random effects of cured group. Also the mean −6 is chosen rather empirically. These are just
19
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possible ways to separate into states (cured or not cured) for the patients. If we made the prior
for σ44 less restrictive and the prior mean of Ri4 larger, we would have more patients with the
probability of cure closer to 0.5 since the random effects model under both groups would fit the
data equally well. On the other hand, if we set the prior mean of Ri4 even smaller, we would have
more unequivocal estimate of probability of cure, that is, many patients would have estimated
probability of cure either closer to 1 or 0. Our experience with various values for both the prior
for σ44 and prior mean of Ri4 found very little effect on the population parameters of the incidence model and failure time model. The prior mean but not the prior distribution of σ44 affects
individual prediction of cure status for some patients. For example, by setting -5 as the prior
mean, we have 108 with predicted cure probability <= 0.05 , 36 with predicted cure probability
>= 0.95, and 97 with predicted cure probability between 0.45 and 0.55 based on posterior draws
of D; while by setting -7 as the prior mean, we have 137 with predicted cure probability <= 0.05,
39 with predicted cure probability >= 0.95, and 84 with predicted cure probability between 0.45
and 0.55. However about 90% of the patients have the difference of predicted cure probability less
than 0.1 under the two different prior means. For the prediction distribution of cancer recurrence
as described in Section 6, we find prediction curves within three years are nearly always very
similar under the assumption of different prior means of Ri4 .
The advantage of adding a cure model to the joint modeling setting is that it provides a
way to model the heterogeneity due to the potential existence of long-term survivors and hence
providing more accurate results. To assess the need for a cure model, we advocate using the
conditional predictive ordinate (CPO). For a specific subject i under model Mr , the CPO is
(r)

defined by CPOi

= fr (xi,obs | X(i),obs ), the conditional density of the observed data for subject i,
(r)

xi,obs , given the observed data X(i),obs for all subjects except i. The CPOi

can be approximated

from MCMC output by a harmonic mean formula (Gelfand 1995),
[i
CPO

(r)

=

(

K
1
1 X
(k)
K
k=1 fr (xi,obs | Ωr )

)−1
(k)

Computation of this approximation involves evaluation of fr (xi,obs | Ωr ) for each draw of the
(k)

population parameters Ωr . For a failed patient, the evaluation of fr (xi,obs | Ωr ) requires integration with respect to random effects Ri and for a censored patient, it requires further integration
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with respect to latent variable Di . Simple simulation studies (without longitudinal data) in Yu
(2004) found that CPO has better performance than the Bayesian information criterion (BIC)
and the Bayes factors for assessing whether or not a model needed a cure component for survival
data. By applying the CPO criteria to our prostate cancer study, we found that the difference
P
(r)
in the summation of log-CPO, ni=1 log(CPOi ) is 172 for joint models with cure models and
without cure models. This supports the need for a cure component in the model.

8

Discussion

In prostate cancer, if the cancer cells are confined to the organ, there is high chance of killing
these cancer cells by radiation and hence curing the patient of prostate cancer. These people
will not experience recurrence of cancer and the probability of having recurrence is 0. However if
cancer cells are not confined to the organ or not completely killed by radiation, then the patient is
subject to recurrence. This is the biological reason for including a cure component in the model.
Yet we never observe cure for a patient if he is censored (had not experienced recurrence yet).
The logistic model provides estimation for the chance of being cured for such patients.
One issue that arises because of patients who received HT due to elevated PSA is dependent
censoring. For such patients, had they not received HT, they would very likely experience cancer
recurrence soon. The effect of HT postponed the time to recurrence. Adding HT as a time
dependent covariate in a hazard model may not be quite correct from a causal inference viewpoint,
but it maybe satisfactory for predictions. The decision to give HT is usually based on the value
and slope of PSA, and these two variables are already in the model, thus adding HT to the model
helps reduce the possible bias since for those patients, the observed time is delayed by HT.
The disadvantage of our model is that it is highly parameterized. With such complicated
modeling, interpretation of the parameters can be hard, and furthermore there can be identifiability problems with cure models(Farewell 1986 and Li et al. 2001). On the other hand, the
slow progressive nature of prostate cancer also means that recurrences are possible many years
after the initial treatment. Thus despite the strong scientific rationale for a cure component, it
may be possible to fit these data without using a cure model. However, use of the CPO statistic
suggests that models including a cured component give a better fit to the data. In this way the
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cure component can simply be regarded as a way to add flexibility to the model.
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